Tango Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Tango Therapeutics

04/11/2022 17:24

* Tango Therapeutics Inc  TNGX.OQ   TNGX.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 7
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 18.4% decrease in revenue to $5.536 million from $6.79
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tango Therapeutics
Inc is
for a loss of 32 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tango
Therapeutics Inc is $13.5​, above​ its last closing price
of $7.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.32       -0.32      -0.28     Beat    13.6
 Mar. 31 2022  -0.28       -0.28      -0.29     Missed  -4.3
 Dec. 31 2021              -0.27      -0.25     Beat    7.4​
 Sep. 30 2021  -0.28       -0.28      -0.28     Met     0.7
 ​​                                                     
                                                        ​
 This summary was machine generated November 4 at 17:24 GMT.  All
figures in US dollars  unless otherwise stated